12:00 PM – 1:00 PM – Registration and Lunch

12:45 PM - 1:00 PM - Opening Remarks - Richard Champlin, MD, The University of Texas M. D. Anderson Cancer Center

1:00 PM – 3:30 PM

1. Stefan Ciurea, MD, The University of Texas M. D. Anderson Cancer Center – Detection of donor-specific anti-HLA antibodies and treatment of allosensitized recipients prior to haploidentical stem cell transplantation

2. Franco Aversa, MD, University of Parma – Haploidentical HSCT: from positive to negative selection

3. Franco Locatelli, MD, PhD, Ospedale Pediatrico Bambino Gesu, Rome, University of Pavia – Depletion of alpha/beta T cells: the new gold standard in manipulated haploidentical HSCT?

4. Ephraim Fuchs, MD, Johns Hopkins Sidney Kimmel Comprehensive Cancer Center – HLA-haploidentical bone marrow transplantation with high dose, post-transplantation cyclophosphamide

5. Paul O’Donnell, MD, Fred Hutchinson Cancer Research Center – Low rates of relapse and chronic GVHD after transplantation of PBSC from haploidentical donors

3:30 PM – 4:00 PM Refreshment Break (Poster Viewing)

4:00 PM – 6:30 PM

1. Yair Reisner, PhD, Weizmann Institute of Science – Novel strategies for non-myeloablative T-cell depleted mega dose haploidentical transplants

2. Wing Leung, MD, PhD, St. Jude Children’s Research Hospital – Haploidentical transplantation in childhood leukemia

3. Gianpietro Dotti, MD, Baylor College of Medicine – Adoptive T-cell therapy with iCaspase9-based suicide gene

4. Hillard Lazarus, MD, Case Western Reserve University – Novel approaches to T cell engineering in myeloablative haploidentical transplants

5. Denis Claude Roy, MD, University of Montreal – Donor lymphocytes selectively photodepleted of alloreactive T cells can fight infections without causing GVHD

6:30 PM – 8:00 PM Buffet Dinner

Program organizers include the below institutions:

The program organizers extend their appreciation to Bellicum Pharmaceuticals, Kiadis Pharma, and Miltenyi Biotec, Inc. for their support